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Abstract 
Purpose: The aim of this study was to evaluate neointimal coverage in the very early phase after 
second-generation drug-eluting stent (DES) implantation using optical coherence tomography (OCT). 
Methods and results: Patients who underwent staged percutaneous coronary intervention within 30 
days after DES implantation were enrolled. OCT was performed to observe DES previously implanted. 
The mean time interval from implantation to OCT examination was 19.9 ± 8.5 days. A total of 10,423 
struts of 54 stents (52 everolimus-eluting stents and 2 zotarolimus-eluting stents) in 42 lesions were 
analyzed. Strut tissue coverage was observed in 71.4 ± 19.3% of the struts, malapposed struts in 2.56 
± 3.38%, struts at the side branch orifice in 2.19 ± 3.09%, and struts with protrusion in 0.97 ± 3.54%. 
Mean tissue thickness on the covered struts was 39.8 ± 14.2 µm. The percentage of stent coverage was 
significantly lower in the overlapping segments than in the non-overlapping segments (46.6 ± 18.8% 
vs. 74.4 ± 20.2%, P<0.05). 
Conclusions: Most of the stent struts were covered by tissue within 30 days after second-generation 
DES implantation. However, the percentage of strut coverage was lower in the overlapping segments 
than in the non-overlapping segments, suggesting that very early interruption of dual antiplatelet 
therapy might result in increased risk of stent thrombosis, even in second-generation DES.  
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Introduction 
Drug-eluting stents (DES) provide reduced rates of restenosis and subsequent repeat 
revascularization compared with bare metal stents (BMS)1. However, delayed arterial healing and 
polymer-induced chronic arterial inflammation, especially in first-generation DES, have been reported 
to increase the risk of stent thrombosis (ST)2-4, which can lead to serious clinical events, such as sudden 
death and acute myocardial infarction2,5. On the other hand, several studies have shown significantly 
less incidence of ST within 30 days after second-generation DES implantation compared with BMS 
and first-generation DES6,7. In contrast with first-generation DES, improved tissue coverage on struts 
of second-generation DES, at an early phase after implantation, has been demonstrated in animal 
models8,9. 
Incomplete neointimal coverage and malapposition of DES struts are important local 
phenomena representing the degree of arterial healing detected by intravascular imaging or 
pathological examination, and their association with ST has been previously reported10,11. Optical 
coherence tomography (OCT) is an intravascular imaging modality with excellent resolution, enabling 
the minute assessment of stent strut coverage and apposition. Thus, recent clinical studies using OCT 
have reported mid-term neointimal coverage on struts of second-generation DES in detail12-14. 
However, there is limited information about strut coverage at the very short-term period after DES 
implantation. In addition, little is known as to whether stent overlap affects early strut coverage. 
Thus, the aim of this study was to evaluate: 1) the early vascular response on the basis of strut 
tissue coverage within 30 days after second-generation DES implantation; and 2) the difference in 
coverage between stent overlapping and non-overlapping segments using OCT. 
 
Materials and methods 
Study design and patient population 
This study was a single-center, prospective, and non-randomized study. Patients who 
underwent staged percutaneous coronary interventions (PCI), separately twice or more within 30 days 
for multiple lesions, and who received second-generation DES implantation at index PCI in our 
hospital between July 1, 2013 and November 30, 2015 were enrolled in this study. Exclusion criteria 
were: (1) patients who had moderate to severe renal dysfunction (estimated glomerular filtration rate 
<45 ml/min/1.73m2); (2) in-stent restenosis lesions; (3) younger than 20 years of age; and (4) refused 
consent for participation. All patients underwent intravascular ultrasound-guided DES implantation, 
through which no obvious stent malapposition at index PCI was confirmed. After PCI, dual-
antiplatelet therapy (DAPT) was continued during the entire study period. OCT was performed within 
30 days after the index DES implantation, at the time of the following staged PCI for other lesions. 
The second-generation DES implanted at index PCI was observed by OCT. The protocol was approved 
by the institutional review boards at Chiba University Hospital, and the study was conducted in 
accordance with regulatory standards and ethics guidelines for clinical studies according to the 
Declaration of Helsinki. All patients provided oral and written informed consent before participation 
in this study. 
Study endpoints 
The primary endpoint of this study was the percentage of covered stent struts assessed by 
OCT within 30 days after DES implantation. Secondary endpoints were tissue thickness on the covered 
struts, percentage of malapposed struts, struts at the side branch orifice, and struts with protrusion. The 
differences in percentage of covered struts and tissue thickness between the stent overlapping 
segments and non-overlapping segments were also evaluated. 
Quantitative angiographic analysis 
Quantitative coronary angiography analysis was performed using a computer-assisted 
automated edge-detection system (CMS, MEDIS, Leiden, The Netherlands). The minimum lumen 
diameter and reference vessel diameter of treated lesions were measured in the view with the most 
severe stenosis and without foreshortening. 
Optical coherence tomography analysis 
Frequency-domain OCT system (ILUMIEN OPTISTM; St. Jude Medical, St. Paul, MN, USA) 
and OCT catheter (DragonflyTM; St. Jude Medical) were used in this study. OCT was performed at a 
pullback speed of 18 mm/sec and rotation speed of 180 frames/sec. Contrast media was continuously 
flushed at a rate of 3.5 to 4 ml/sec for 3 to 4 seconds. All OCT images were stored at our institution, 
and off-line OCT analysis was performed by an experienced cardiologist (M.T.), who was unaware of 
the clinical presentations and lesion characteristics. Cross-sectional OCT images of the stented 
segment were analyzed at 1.0-mm intervals (every 10 frames) by OCT software (ILUMIENTM; St. 
Jude Medical). Each cross-sectional image was screened for quality, and excluded from this study if 
the image had poor quality caused by residual blood, artifact, or reverberation. A metallic strut 
typically appears as a bright signal-intensity structure with dorsal shadowing. Stent and lumen areas 
were measured at each cross-section. OCT-derived restenosis was defined as a lesion with % diameter 
stenosis >50%.  
A covered strut was defined if tissue could be identified above the strut. In the covered struts, 
the tissue thickness was measured from the strut marker to the endoluminal surface of tissue coverage. 
The marker of each strut was placed at the endoluminal leading edge in the midpoint of its long axis, 
and the distance was measured following a straight line connecting this marker with the center of 
gravity of the vessel. Strut apposition was evaluated by measuring the distance between the strut 
marker and the lumen surface. Malapposition was defined if the distance was longer than the stent 
strut thickness plus polymer thickness: >89 μm for everolimus-eluting stent (EES) and >97 μm for 
Resolute zotarolimus-eluting stent (R-ZES). The stent struts located at the level of side branch orifice 
were excluded from the analysis of coverage and apposition. Stent struts with protrusion was defined 
as the projection of irregular tissue with attenuation into the lumen between or over stent struts, and 
were also excluded from the analysis of coverage and apposition. An overlapping segment was defined 
as a cross-section in which a double-strut layer could be identified. In the overlapping segment, struts 
of the inner layer were analyzed and struts of the outer layer were excluded. Tissue coverage and tissue 
thickness in the overlapping versus non-overlapping segments were analyzed only in lesions with stent 
overlapping. 
Statistical analysis 
Continuous variables are presented as mean ± SD and compared using unpaired Student’s t-
test. Categorical variables are presented as numbers and percentage. Statistical analysis was performed 
with SAS version 9.4 (SAS Institute Inc, Cary, North Carolina, USA). A p value <0.05 was considered 
to indicate statistical significance. 
 
Results 
A total of 37 patients were enrolled, and 10,423 struts of 54 stents (52 EES and 2 R-ZES) in 
42 lesions were analyzed. Baseline patient and lesion characteristics of the study population are 
presented in Tables 1 and 2. The indications for index intervention included myocardial infarction in 
15 patients, unstable angina in 5 patients, and stable angina in 17 patients. Seventeen lesions were 
located in the left anterior descending artery, 11 in the left circumflex artery, and 14 in the right 
coronary artery. Two stents with overlapping were implanted in 18 lesions.  
OCT findings are shown in Table 3. There were no serious complications with the OCT 
procedure. The mean time interval from DES implantation to OCT examination was 19.9 ± 8.5 days. 
The mean analyzed length of stented segment was 34.0 ± 11.4 mm and mean stent area was 7.43 ± 
2.77 mm2. No patient demonstrated OCT-derived restenosis. Strut tissue coverage was observed in 
71.4 ± 19.3% of struts, malapposed struts in 2.56 ± 3.38%, struts at the side branch orifice in 2.19 ± 
3.09%, and struts with protrusion were seen in 0.97 ± 3.54%. The mean tissue thickness on the covered 
struts was 39.8 ± 14.2 µm. 
In analysis of 18 patients with stent overlap, 672 struts in the overlapping segments and 4,064 
struts in the non-overlapping segments were analyzed. All stents implanted in these patients were EES, 
and time interval from implantation to OCT examination was 22.3 ± 7.6 days. The percentage of strut 
coverage was significantly lower in the overlapping segments than in the non-overlapping segments 
(46.6 ± 18.8% vs. 74.4 ± 20.2%, P <0.05) (Figure 1A). Mean tissue thickness was not significantly 
different between the overlapping and non-overlapping segments (41.8 ± 13.4 μm vs. 35.6 ± 8.7 μm, 
NS) (Figure 1B). Representative OCT images are shown in Figure 2. 
 
Discussion 
The main findings of this study were as follows: 1) over 70% of struts were covered by tissue 
within 30 days after second-generation DES implantation; 2) mean tissue thickness was 39.8 µm; and 
3) the percentage of strut coverage was significantly lower in the overlapping segments than in the 
non-overlapping segments. 
Detailed assessment of neointimal coverage on the struts of second-generation DES, 
including EES and R-ZES, using OCT has been previously reported in several clinical studies. These 
studies showed that the percentages of covered struts were 88.4% at 1 month15, 95.5% at 2 months15, 
93.6-95.3% at 3 months12,15, 92.1-94.5% at 6 months16, 95.7-96.7% at 9 months13,17, and 92.6-94.2% 
at 13 months14, respectively. Another OCT study in patients with ST-segment elevation myocardial 
infarction demonstrated high rates of strut coverage reaching >90% at 2 weeks, and the degree of 
coverage was comparable among BMS and 3 types of DES18 
It has been reported that incomplete strut coverage is one of the risk factors for ST10,11. 
Recently, lower incidence of ST after second-generation DES implantation compared with both first-
generation DES and BMS has been shown in several meta-analyses19. In previous human autopsy 
analysis, greater strut coverage with less inflammation and fibrin deposition at 100 to 500 days after 
EES implantation compared with first-generation DES20 was demonstrated. Furthermore, previous 
randomized controlled studies have shown significantly less early ST in second-generation DES than 
in BMS and first-generation DES6,7. Although several animal studies have demonstrated the improved 
tissue coverage on the struts of second-generation DES compared with first-generation DES8,9, there 
are few studies investigating very short-term strut coverage after second-generation DES implantation 
in real-world clinical settings. The present study showed that the percentage of stent strut coverage 
was 71.4% 19.9 ± 8.5 days after implantation, suggesting that second-generation DES has a good 
vascular response. This result might be one of the supportive reasons for lower risk of early ST in 
second-generation DES. 
The mean thickness of tissue coverage was 39.8 µm in the present study. It was quite thin, 
but appeared to be reasonable, when estimated on the basis of previous studies demonstrating 
progressive increase in neointimal thickness measured by OCT as 38.9 µm at 1 month15, 70.6 µm at 2 
months15, 54.1-75.0 µm at 3 months12,15, 87-102 µm at 6 months16, 109-139 µm at 9 months13,17, and 
116-142 µm at 13 months14 after second-generation DES implantation. Generally, tissue formation 
covering stent struts after implantation undergoes transitions, from fibrin, extracellular matrix, or 
inflammatory cells to neointima. In qualitative OCT assessment, tissue with few smooth muscle cells 
and rich fibrin or extracellular matrix is shown as tissue formation with relatively low-intensity 
signal21,22. On the other hand, neointima, with mainly smooth muscle cells and collagen fibers, is 
shown as smooth and homogeneous tissue coverage with a relatively high-intensity signal. Therefore, 
tissue characterization of strut coverage can be substantially done using OCT. In the present OCT 
study, however, it was difficult to evaluate tissue characterization due to the degree of thinness of the 
tissue, although the tissue covering the stent struts might be composed of fibrin and extracellular 
matrix, considering the timing of examination. In a previous animal study, the significant difference 
in optical density measured by optical frequency domain imaging between fibrin and neointima on 
stent struts was demonstrated, and it was suggested that the optical density could provide information 
on the type of the tissue23. Further study is required to investigate tissue characterization of thin 
neointima. 
Several studies have reported that overlapping DES may delay arterial healing and promote 
inflammation, possibly resulting in higher risk of negative clinical outcomes, because double layers 
of DES might cause higher dose exposure and increased polymer toxicity to the vessel wall24-26. 
Animal model studies have reported incomplete neointimal healing in the overlapping segments 
compared with non-overlapping segments at early phase after DES implantation25. Although stent 
overlap with second-generation DES has been associated with better long-term clinical outcome, such 
as lower rates of major adverse cardiac event, ST, and target vessel revascularization compared with 
first-generation DES27,28, the impact of stent overlap on neointimal proliferation has been unclear, 
especially in the short-term period. The present study showed that the percentage of stent coverage 
was significantly lower in the overlapping segments than in the non-overlapping segments. This result 
suggests that DAPT interruptions in very early phase after DES implantation with overlapping stents 
might result in higher risk of ST. 
The present study has several limitations. This is a single-center, non-randomized study, and 
the number of enrolled patients was small. Only patients with multivessel coronary lesions and without 
moderate to severe renal dysfunction were enrolled. Medium and long-term OCT follow-up were not 
performed. 
 
Conclusions 
Most of the stent struts were covered by tissue within 30 days after second-generation DES 
implantation. However, the percentage of strut coverage was lower in the overlapping segments than 
in the non-overlapping segments, suggesting that very early interruption of DAPT might result in 
increased risk of ST, even in second-generation DES. 
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Figure legends 
Figure 1. Comparison between the overlapping (672 struts) vs. non-overlapping (4,064 struts) 
segments in lesions with stent overlapping. (A) Percentage of covered strut. (B) Mean tissue thickness 
on the covered struts. 
 
Figure 2. Representative OCT images. (A) Overlapping segment (red arrows indicating uncovered 
struts) (B) Non-overlapping segment (yellow arrows indicating covered struts). 
 
 
Table 1. Baseline patient characteristics 
 N=37 
Age (years) 64.6 ± 11.4 
Male 33 (89) 
Body mass index (kg/m2) 24.5 ± 3.1 
Hypertension 31 (84) 
Dyslipidemia 26 (70) 
Diabetes mellitus 12 (32) 
Current smoker 21 (57) 
Family history of coronary artery disease 6 (16) 
Prior myocardial infarction 0 (0) 
Prior PCI 6 (16) 
Prior CABG 0 (0) 
Indication for index intervention  
     Myocardial infarction 15 (41) 
     Unstable angina 5 (13) 
     Stable angina 17 (46) 
Dual anti-platelet therapy 37 (100) 
Data given as mean ± SD or n (%). PCI: percutaneous coronary intervention;  
CABG: coronary artery bypass grafting; IVUS: intravascular ultrasound. 
 
 
 
 
 
 
 
 
Table 2. Baseline lesion characteristics 
 N=42 
Target vessel  
   LAD 17 (41) 
     LCx 11 (26) 
     RCA 14 (33) 
Stent type  
     EES 40 (95) 
     R-ZES 2 (5) 
Type B2 or C lesion 30 (71) 
Stent diameter (mm) 3.02 ± 0.37 
Maximum balloon diameter (mm) 3.61 ± 0.71 
Maximum inflation pressure (atm) 18.6 ± 2.94 
Overlapping segments 18 (43) 
Total stent length per lesion (mm) 40.4 ± 15.8 
Reference vessel diameter (mm) 2.62 ± 0.61 
Minimum lumen diameter (mm) 0.46 ± 0.37 
Data given as mean ± SD or n (%). LAD: left anterior descending artery; 
LCx: left circumflex artery; RCA: right coronary artery;  
EES: everolimus-eluting stent; R-ZES: Resolute zotarolimus-eluting stent 
 
 
 
 
 
 
 
 
 
Table 3. Optical coherence tomography (OCT) findings 
 
 
 N=42 
Cross-sectional analysis 
Time interval to OCT (days) 19.9 ± 8.52 
Stent length per lesion (mm) 34.0 ± 11.4 
Minimum lumen area (mm2) 5.68 ± 2.23 
Minimum lumen diameter (mm) 2.40 ± 0.47 
Mean stent area (mm2) 7.43 ± 2.77 
Mean lumen area (mm2) 7.33 ± 2.89 
Restenosis 0 (0) 
Strut-level analysis 
Total number of stent struts 10,423 
% covered struts 71.4 ± 19.3 
% apposed struts 97.4 ± 16.7 
% apposed and covered struts 71.0 ± 19.3 
% apposed and uncovered struts 26.5 ± 17.9 
% malapposed struts 2.56 ± 3.38 
% malapposed and covered struts 0.41 ± 0.79 
% malapposed and uncovered struts 2.15 ± 3.10 
% struts at the side branch orifice 2.19 ± 3.09 
% struts with protrusion 0.97 ± 3.54 
Mean tissue thickness (μm) 39.8 ± 14.2 
Data given as mean ± SD or n (%). 
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